Home Cart Sign in  
Chemical Structure| 906673-24-3 Chemical Structure| 906673-24-3

Structure of Crisaborole
CAS No.: 906673-24-3

Chemical Structure| 906673-24-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AN-2728 is a topically administered, boron-containing, anti-inflammatory compound that inhibits PDE4 activity with an IC50 of 0.49 μM and thereby suppresses the release of TNFalpha, IL-12, IL-23 and other cytokines.

Synonyms: AN-2728; PF-06930164; Crisaborole, Eucrisa

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Crisaborole

CAS No. :906673-24-3
Formula : C14H10BNO3
M.W : 251.05
SMILES Code : OB1OCC2=C1C=CC(OC1=CC=C(C=C1)C#N)=C2
Synonyms :
AN-2728; PF-06930164; Crisaborole, Eucrisa
MDL No. :MFCD17169940
InChI Key :USZAGAREISWJDP-UHFFFAOYSA-N
Pubchem ID :44591583

Safety of Crisaborole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03645057 Atopic Dermatitis Phase 3 Not yet recruiting August 31, 2020 -
NCT03250663 Mild to Moderate Atopic Dermat... More >>itis Less << Phase 1 Recruiting August 1, 2019 United States, North Carolina ... More >> Wake Forest University Heath Sciences Recruiting Winston-Salem, North Carolina, United States, 27157 Less <<
NCT03770858 - Not yet recruiting December 2019 United States, Illinois ... More >> Northwestern University Not yet recruiting Chicago, Illinois, United States, 60611 Contact: Dermatology CTU    312-503-5944    NUdermatologyCTU@northwestern.edu Less <<
NCT00762658 Psoriasis Phase 1 Completed - Germany ... More >> Bioskin GmbH Hamburg, Germany, 10117 Less <<
NCT03351114 Morphea PHASE2 COMPLETED 2020-03-10 Duke University, Durham, North... More >> Carolina, 27710, United States Less <<
NCT00763204 Psoriasis Phase 1 Completed - Germany ... More >> Bioskin GmbH Hamburg, Germany, 10117 Less <<
NCT03356977 Atopic Dermatitis Phase 4 Recruiting February 23, 2019 -
NCT03260595 Healthy Atopi... More >>c Dermatitis Less << Phase 1 Completed - Japan ... More >> Medical Corporation Heishinkai OPHAC Hospital Osaka-shi, Osaka, Japan, 532-0003 Less <<
NCT03233529 Dermatitis, Atopic Phase 2 Completed - Canada, Quebec ... More >> Innovaderm Research Incorporated Montreal, Quebec, Canada, H2K 4L5 Less <<
NCT03760042 Healthy Phase 1 Recruiting April 2, 2019 United States, Connecticut ... More >> Pfizer New Haven Clinical Research Unit Recruiting New Haven, Connecticut, United States, 06511 Less <<
NCT03567980 Seborrheic Dermatitis PHASE4 COMPLETED 2021-05-12 Dermatology at the Whitaker Cl... More >>inic, Birmingham, Alabama, 35249, United States Less <<
NCT00755196 Psoriasis Phase 2 Completed - Mexico ... More >> IMIC Mexico City, Distrito Federal, Mexico, 06700 Less <<
NCT01029405 Psoriasis Phase 2 Completed - Mexico ... More >> Mexico City, D.f., Mexico Zapopan, Jalisco, Mexico Monterrey, Nuevo Leon, Mexico Monterrey, Nuevo León, Mexico Chihuahua, Mexico San Luis Potosí, Mexico Less <<
NCT03539601 Atopic Dermatitis Phase 4 Recruiting May 25, 2020 United States, Arkansas ... More >> Dermatology Trial Associates Recruiting Bryant, Arkansas, United States, 72022 United States, California California Dermatology & Clinical Research Institute Recruiting Encinitas, California, United States, 92024 United States, Florida Park Avenue Dermatology Recruiting Orange Park, Florida, United States, 32073 Forward Clinical Trials, Inc. Recruiting Tampa, Florida, United States, 33624 United States, Kentucky DS Research Recruiting Louisville, Kentucky, United States, 40241 United States, North Carolina M3-Wake Research, Inc. Recruiting Raleigh, North Carolina, United States, 27612 United States, Texas Arlington Research Center Inc Recruiting Arlington, Texas, United States, 76011 United States, Virginia Virginia Clinical Research, Inc Recruiting Norfolk, Virginia, United States, 23502 Less <<
NCT01301508 Dermatitis, Atopic Phase 2 Completed - Australia, New South Wales ... More >> Anacor Investigational Site Kogarah, New South Wales, Australia, 2217 Australia, Queensland Anacor Investigational Site Brisbane, Queensland, Australia, 4000 Anacor Investigational Site Woolloongabba, Queensland, Australia, 4102 Australia, South Australia Anacor Investigational Site Adelaide, South Australia, Australia, 5000 Australia, Victoria Anacor Investigational Site Box Hill, Victoria, Australia, 3128 Anacor Investigational Site Carlton, Victoria, Australia, 3053 Anacor Investigational Site Clayton, Victoria, Australia, 3168 Anacor Investigational Site Fitzroy, Victoria, Australia, 3065 Anacor Investigational Site Parkville, Victoria, Australia, 3050 Australia, Western Australia Anacor Investigational Site Fremantle, Western Australia, Australia, 6160 Anacor Investigational Site Nedlands, Western Australia, Australia, 6009 Anacor Investigational Site Subiaco, Western Australia, Australia, 6008 Anacor Investigational Site Victoria Park, Western Australia, Australia, 6100 Less <<
NCT01029405 - Completed - -
NCT01301508 - Completed - -
NCT00755196 - Completed - -
NCT00759161 Psoriasis Phase 2 Completed - Mexico ... More >> IMIC Mexico City, Distrito Federal, Mexico, 06700 Less <<
NCT02118766 Dermatitis, Atopic Phase 3 Completed - United States, Georgia ... More >> Anacor Investigational Site Stockbridge, Georgia, United States Less <<
NCT00759161 - Completed - -
NCT02118766 - Completed - -
NCT02118792 Dermatitis, Atopic Phase 3 Completed - United States, Virginia ... More >> Anacor Investigational Site Henrico, Virginia, United States Less <<
NCT01258088 Plaque-type Psoriasis Phase 1 Completed - Australia ... More >> CMAX (A Division of IDT Australia Ltd) Adelaide, Australia, 5000 Less <<
NCT01300052 Psoriasis Phase 2 Completed - United States, Connecticut ... More >> The Savin Center New Haven, Connecticut, United States, 06511 United States, Kentucky Dermatology Specialists, PSC Louisville, Kentucky, United States, 40202 United States, Minnesota Minnesota Clinical Study Center Fridley, Minnesota, United States, 55432-3133 United States, Nevada Karl G. Heine, MD Dermatology Henderson, Nevada, United States, 89052 United States, New Mexico Academic Dermatology Associates Albuquerque, New Mexico, United States, 87106 United States, North Carolina Dermatology Consulting Services High Point, North Carolina, United States, 27262 United States, Oregon Oregon Medical Research Center Portland, Oregon, United States, 97223 United States, Texas DermResearch, Inc Austin, Texas, United States, 78759 J&S Studies, Inc. College Station, Texas, United States, 77845 The Center for Skin Research Houston, Texas, United States, 77056 Less <<
NCT01602341 - Completed - -
NCT02118792 - Completed - -
NCT01652885 Dermatitis, Atopic Phase 1 Phase 2 Completed - United States, California ... More >> Anacor Investigational Site Fremont, California, United States, 94538 Anacor Investigational Site San Diego, California, United States, 92123 United States, Indiana Anacor Investigational Site Indianapolis, Indiana, United States, 46256 United States, North Carolina Anacor Investigational Site High Point, North Carolina, United States, 27262 Anacor Investigational Site Winston-Salem, North Carolina, United States, 27104 United States, Texas Anacor Investigational Site Houston, Texas, United States, 77030 Less <<
NCT01602341 Dermatitis, Atopic Phase 2 Completed - United States, California ... More >> Anacor Investigational Site Fremont, California, United States United States, Florida Anacor Investigational Site Miami, Florida, United States United States, Kentucky Anacor Investigational Site Lousiville, Kentucky, United States United States, Michigan Anacor Investigational Site Detroit, Michigan, United States United States, New Mexico Anacor Investigational Site Albuquerque, New Mexico, United States United States, New York Anacor Investigational Site Stony Brook, New York, United States United States, North Carolina Anacor Investigational Site High Point, North Carolina, United States United States, Oregon Anacor Investigational Site Portland, Oregon, United States United States, Tennessee Anacor Investigational Site Knoxville, Tennessee, United States United States, Utah Anacor Investigational Site Salt Lake City, Utah, United States United States, Virginia Anacor Investigational Site Norfolk, Virginia, United States Australia, Australian Capital Territory Anacor Investigational Site Phillip, Australian Capital Territory, Australia, 2606 Australia, New South Wales Anacor Investigational Site Kogarah, New South Wales, Australia, 2217 Australia, Queensland Anacor Investigational Site Wooloongabba, Queensland, Australia Australia, Victoria Anacor Investigational Site Box Hill, Victoria, Australia Anacor Investigational Site Parkville, Victoria, Australia Australia, Western Australia Anacor Investigational Site Fremantle, Western Australia, Australia, 6160 Less <<
NCT01300052 - Completed - -
NCT01652885 - Completed - -
NCT04023084 Atopic Dermatitis|Eczema PHASE4 COMPLETED 2022-02-11 Ann & Robert H. Lurie Children... More >>'s Hospital of Chicago, Chicago, Illinois, 60611, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.98mL

0.80mL

0.40mL

19.92mL

3.98mL

1.99mL

39.83mL

7.97mL

3.98mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories